Results 171 to 180 of about 22,306,541 (256)

Safety of BromAc<sup>®</sup> with Mitomycin C during hyperthermic intraperitoneal chemotherapy (HIPEC): a preclinical study. [PDF]

open access: yesAm J Cancer Res
Mekkawy AH   +9 more
europepmc   +1 more source

Scrotal wall necrosis after hipec using mitomycin-c: Case report and review of the literature. [PDF]

open access: yesInt J Surg Case Rep
El Halabieh MA   +5 more
europepmc   +1 more source
Some of the next articles are maybe not open access.

Related searches:

Intermediate Outcomes of a Novel Standalone Ab Externo SIBS Microshunt With Mitomycin C

American Journal of Ophthalmology, 2020
PURPOSE To determine the efficacy, risk factors for failure, and adverse events of a standalone novel ab-externo SIBS microshunt with mitomycin C (MMC) during 1-year follow-up. DESIGN Retrospective, interventional case series.
Matthew B Schlenker   +2 more
exaly   +2 more sources

Mitomycin C

Monographs In Contact Allergy, 2022
Anton C. de Groot
openaire   +2 more sources

A randomized controlled trial of adjuvant mitomycin‐c in endoscopic surgery for laryngotracheal stenosis

The Laryngoscope, 2020
Topical mitomycin‐C (MMC) application is a commonly accepted adjuvant therapy in the surgical treatment for laryngotracheal stenosis (LTS). However, the efficacy of MMC has not been examined in a prospective, randomized clinical trial in humans. We aimed
K. Yung, Joseph Chang, M. Courey
semanticscholar   +1 more source

Mitomycin C.

Cancer chemotherapy and biological response modifiers, 1990
The mitomycins are antitumor antibiotics that are under investigation now for more than 30 years. Mitomycin C (MMC) is the best investigated subtype. It serves as a prototype for drugs with bioreductive alkylation, which is a unique feature of this class. MMC is mainly active under anaerobic circumstances.
J, Verweij, H M, Pinedo
  +9 more sources

Mitomycin C extravasation injuries

Cancer, 1983
Mitomycin C extravasation produces a chronic painful ulceration similar to that of adriamycin. Pain marks the extravasation of this chemotherapeutic agent when it occurs. A complaint of pain during mitomycin administration should prompt immediate cessation of infusion and regular frequent follow-up.
L C, Argenta, E K, Manders
openaire   +2 more sources

Home - About - Disclaimer - Privacy